Tempramed signs exclusive Turkish distribution deal

Executive Summary

• Tempramed Technologies Ltd. has entered into a definitive exclusive distribution agreement with Dolfin Saglik Urunleri to market and sell its VIVI line of medication temperature-stabilizing products throughout Turkey.
• The partnership leverages Dolfin Saglik’s established national presence in Turkey’s medical device market to address a significant commercial opportunity in the country’s large diabetes population (approx. 10 million people).
• This agreement is part of Tempramed’s broader strategic expansion to transition from direct-to-consumer channels toward retail pharmacy networks, regional distributors, and institutional healthcare partners.

Key Details

• Parties Involved: Tempramed Technologies Ltd. (VIVI.CNSX) and Dolfin Saglik Urunleri.
• Agreement Type: Definitive exclusive distribution agreement.
• Territory: Turkey.
• Products Covered: Tempramed’s VIVI line of medication temperature-stabilizing products, including VIVICap and VIVIEpi, which use patented smart insulation technology to protect temperature-sensitive medications (insulin, Epi Pens, biologics, fertility medications, GLP-1 therapies) from heat and cold without requiring conventional cooling.
• Partner Profile: Dolfin Saglik, founded in 2002, is a leading Turkish medical device and supplies company serving public/private hospitals, emergency services, educational institutions, and provincial health directorates.
• Market Context: Turkey has one of the highest prevalence rates of diabetes in Europe, with over one million insulin users and an additional number of GLP-1 users, creating a significant demand for temperature-regulated medication protection.
• Strategic Goals: The partnership aims to accelerate market penetration among insulin-dependent and GLP-1 using patients and providers, including hospitals, family medicine clinics, diabetes educators, and national purchasing entities.
• Company Strategy: Tempramed plans to continue expanding its product offering globally, adding new products and verticals, and leveraging its direct-to-consumer business to drive new institutional and B2B partnerships over the next 12 months.

Notable Quotes

• Ron Nagar, CEO of Tempramed: "As one of Turkey's leading medical distributors... Dolfin's deep relationships across emergency care, hospitals, educational institutions and individual patient networks make them a powerful commercialization partner. This agreement accelerates our expansion into a large and fast-growing diabetes market..."
• Tolga Orucoglu, General Manager of Dolfin Saglik: "We have been dedicated to bringing innovative medical solutions to Turkey for over two decades, and VIVI is unlike anything currently available in our market... Tempramed's product portfolio provides a validated solution that delivers confidence, efficacy and safety without requiring cooling or daily maintenance."